A Study of LY3857210 in Healthy Participants

Overseen By There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Eli Lilly and Company

Disqualifiers: Implants, Claustrophobia, MRI findings, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 4

Duration: 1 day

10 Participants Needed

Trial Summary

Do I have to stop taking my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. However, since the study involves healthy participants, it's possible that you may need to avoid certain medications. Please check with the study team for specific guidance.

What is the purpose of this trial?

This trial tests a new drug, LY3857210, in healthy people to see how it behaves in the brain using special brain scans. The study also checks if the drug is safe and tolerable.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

Inclusion Criteria

Overtly healthy male or female participants as determined by medical evaluation

Have body weight ≥ 45 kilograms (kg) and body mass index (BMI) within the range 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive)

You are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive a single oral dose of LY3857210 and undergo PET scans to measure brain receptor occupancy

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4-5 weeks

Up to 3 visits (in-person)

Treatment Details

Interventions

• LY3857210

Participant Groups

Group I: LY3857210 Experimental Treatment 1 Intervention

Single doses of LY3857210 administered orally.

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University